Literature DB >> 8599865

A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve.

S Ghazal-Aswad1, A H Calvert, D R Newell.   

Abstract

The aim of this study was to develop and validate a simple and rapid method for the estimation of the area under the free carboplatin plasma concentration versus time curve (AUC). The relationship between the carboplatin AUC and the total plasma platinum (Pt) concentration 24 h after treatment was studied using data from 49 patients treated with 20-1600 mg/m2 carboplatin as a 60-100 min infusion (median 60 min). The relationship was confirmed by the in vitro incubation of carboplatin in human plasma and prospectively validated in 13 ovarian cancer patients. Free carboplatin was separated by ultrafiltration (MW cut off 30,000), and free and total Pt measured by atomic absorption spectrophotometry. There was a linear relationship in vivo between the 24 h (median 24.4; range 16.3-27.3 h) total plasma Pt concentration (microM) and free carboplatin AUC (mg/ml.min): AUC=(24 h Pt+0.3)/0.82 (r2=0.93, AUC median 5.8 (0.13-28)mg/ml.min, 24h Pt median 4.4 (0.1-23) microM). A similar relationship was observed in vitro [AUC =(24h Pt +0.1)/0.93 (r2=0.98, AUC median 7.9 (2.0-17) mg/ml.min, 24 h Pt median 7.1 (1.8-15) microM)]. The relationship derived from the in vivo data gave an unbiased and reasonably accurate estimate of the measured carboplatin AUC in 13 patients (AUC =5.1-8.7 mg/ml.min, GFR=59-129 ml/min, infusion time 30-45 min, 24 h sampling time 22.9-24.5 h), giving a percentage mean error of -4.2% and root mean squared percentage error of 11.5%. These results show that the analysis of a single blood sample taken 24 h after carboplatin administration can be used to produce an unbiased and reasonably accurate measure of the free carboplatin AUC. Unlike published limited sampling strategies, this method is not complicated by the need to accurately control the duration of the carboplatin infusion or the time at which the sample is taken.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8599865     DOI: 10.1007/s002800050408

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors.

Authors:  A Horwich; D P Dearnaley; J Nicholls; G Jay; M Mason; S Harland; M J Peckham; W F Hendry
Journal:  J Clin Oncol       Date:  1991-01       Impact factor: 44.544

2.  Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.

Authors:  L J van Warmerdam; S Rodenhuis; O van Tellingen; R A Maes; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.

Authors:  D R Newell; R A Eeles; L A Gumbrell; F E Boxall; A Horwich; A H Calvert
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  A limited sampling method for estimation of the carboplatin area under the curve.

Authors:  B T Sørensen; A Strömgren; P Jakobsen; A Jakobsen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

6.  Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin.

Authors:  D R Newell; Z H Siddik; L A Gumbrell; F E Boxall; M E Gore; I E Smith; A H Calvert
Journal:  Eur J Cancer Clin Oncol       Date:  1987-09

7.  Carboplatin dose in combination chemotherapy for testicular cancer.

Authors:  S J Harland; L A Gumbrell; A Horwich
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

Review 8.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

9.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.

Authors:  S J Harland; D R Newell; Z H Siddik; R Chadwick; A H Calvert; K R Harrap
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

10.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

Authors:  A H Calvert; D R Newell; L A Gumbrell; S O'Reilly; M Burnell; F E Boxall; Z H Siddik; I R Judson; M E Gore; E Wiltshaw
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

View more
  12 in total

Review 1.  Pharmacokinetically guided administration of chemotherapeutic agents.

Authors:  H J van den Bongard; R A Mathôt; J H Beijnen; J H Schellens
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

2.  Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients.

Authors:  Toru Ishibashi; Yoshitaka Yano; Takayoshi Oguma
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

3.  Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.

Authors:  Vivian E von Gruenigen; Helen Q Huang; Jan H Beumer; Heather A Lankes; William Tew; Thomas Herzog; Arti Hurria; Robert S Mannel; Tina Rizack; Lisa M Landrum; Peter G Rose; Ritu Salani; William H Bradley; Thomas J Rutherford; Robert V Higgins; Angeles Alvarez Secord; Gini Fleming
Journal:  Gynecol Oncol       Date:  2017-01-13       Impact factor: 5.482

Review 4.  Clinical pharmacokinetics and dose optimisation of carboplatin.

Authors:  S B Duffull; B A Robinson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

Review 5.  Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology.

Authors:  Jennifer H Martin; Mohamed Saleem; David Looke
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

6.  Effects of storage on the binding of carboplatin to plasma proteins.

Authors:  K Erkmen; M J Egorin; L M Reyno; R Morgan; J H Doroshow
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 7.  A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.

Authors:  Gabriel W Loh; Lillian S L Ting; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.

Authors:  V R Nannan Panday; L J van Warmerdam; M T Huizing; W W Ten Bokkel Huinink; J B Vermorken; G Giaccone; C H Veenhof; J H Schellens; J H Beijnen
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

9.  Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines.

Authors:  Rita Otvös; Henriette Skribek; Lorand L Kis; Annunziata Gloghini; Laszlo Markasz; Emilie Flaberg; Staffan Eksborg; Jozsef Konya; Lajos Gergely; Antonino Carbone; Laszlo Szekely
Journal:  BMC Cancer       Date:  2011-10-12       Impact factor: 4.430

10.  Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells.

Authors:  Laszlo Markasz; György Stuber; Emilie Flaberg; Asa Gustafsson Jernberg; Staffan Eksborg; Eva Olah; Henriette Skribek; Laszlo Szekely
Journal:  BMC Cancer       Date:  2006-11-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.